Key result
Moderate remnant cholesterol is linked to ~17% lower 24-month mortality in STEMI vs lowest levels.
Why the study?
What is the association between remnant cholesterol levels and the risk of in-hospital and 24-month all-cause mortality in patients with STEMI?
Cohort (n=14,928)
What is the association between remnant cholesterol levels and the risk of in-hospital and 24-month all-cause mortality in patients with STEMI?
In STEMI patients, remnant cholesterol levels exhibit a U-shaped association with in-hospital and 24-month mortality, with optimal survival observed at intermediate levels (0.42 to 0.94 mmol/L).
Intermediate remnant cholesterol may aid STEMI risk stratification; leaves open causal role and need for randomized trials before practice change.
Background Remnant cholesterol is emerging as residual lipid risk factors of coronary heart diseases supported by substantial evidence. Nevertheless, studies on the association between remnant cholesterol levels and prognosis in patients with STEMI are insufficient, and they were conducted in small sample size. Purpose The objective of this study was to investigate the relationship between remnant cholesterol levels and the risk of in-hospital and long-term mortality in STEMI patients in a large prospective cohort, the CAMI registry. Methods In this study, patients with STEMI enrolled from the CAMI registry were categorised by the quartile of remnant cholesterol distribution. remnant cholesterol was calculated by the equation: total cholesterol minus LDL cholesterol minus HDL cholesterol. The primary endpoints were in-hospital mortality and 24 months all-cause mortality. Cox-regression models were used to estimate the association between remnant cholesterol and risk of mortality. Results A total of 14928 patients with STEMI were included in the main analysis and divided by the inter-quartile of remnant cholesterol. The lower quartile, median and upper quartile of remnant cholesterol were 0.42mmol/L, 0.64mmol/L and 0.94mmol/L, respectively. We observed a U-shaped association between remnant cholesterol levels and in-hospital and long-term mortality. The in-hospital mortality was 5.8% in lowest quartile, 4.1% in the second quartile, 4.3% in the third quartile and 4.5% in the highest quartile(P=0.0020). After multivariable adjustment, the decrease in in-hospital mortality was still observed in the second quartile[HR (95%CI): 0.764 (0.620-0.942), P=0.0118]. In the 24-month follow-up, the all-cause mortality rate was 13.0% in the first quartile, 10.5% in the second quartile, 10.2% in the third quartile and 10.4% the fourth quartile (P=0.0003). After multivariable adjustment, we found a lower risk in the second and the third quartile[Q2: HR (95%CI): 0.835 (0.727-0.958),P=0.0103;Q3: HR (95%CI): 0.858 (0.747-0.987), P=0.0319]. Conclusions The analysis of STEMI patients demonstrates that both very low and elevated remnant cholesterol levels were associated with higher risk of in-hospital mortality and long-term mortality. A better prognosis was observed in the second and third quartiles of remnant cholesterol, ranging from 0.42mmol/L to 0.94mmol/L. Comprehensive assessment of the lipid profile, including remnant cholesterol, may play a relevant role in the primary and secondary prevention of cardiovascular disease. Enhanced lifestyle management alongside developed lipid-lowering therapy is highly underscored in the STEMI patients to improve prognosis.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a cohort in ST-segment elevated myocardial infarction (STEMI) (n=14,928). Remnant cholesterol levels (second quartile: 0.42-0.64 mmol/L) vs. Lowest quartile of remnant cholesterol (<0.42 mmol/L) was evaluated on In-hospital mortality and 24-month all-cause mortality (HR 0.835, 95% CI 0.727-0.958, p=0.0103). Remnant cholesterol in the 2nd quartile (0.42-0.64 mmol/L) was associated with lower in-hospital (HR 0.764; 95% CI 0.620-0.942) and 24-month mortality (HR 0.835; 95% CI 0.727-0.958) vs Q1 in STEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: